Volume 95 Issue 19 | p. 12 | Concentrates
Issue Date: May 8, 2017

Sosei buys stake in RNA therapy firm

Department: Business
Keywords: nucleic acids, small activating RNA

Japan’s Sosei Group will spend $45 million to acquire a 25.6% ownership stake in MiNA Therapeutics and an option to potentially acquire all of the London-based firm. MiNA’s lead compound is MTL-CEBPA, a small activating RNA that is in the midst of Phase I/IIa clinical trials as an advanced liver cancer treatment. Sosei says MiNA will complement Heptares Therapeutics, a London-based developer of drugs targeting G protein-coupled receptors that Sosei acquired in 2015.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment